These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
811 related articles for article (PubMed ID: 32369402)
1. Coronavirus disease 2019 (COVID-19) and the renin-angiotensin system: A closer look at angiotensin-converting enzyme 2 (ACE2). Zemlin AE; Wiese OJ Ann Clin Biochem; 2020 Sep; 57(5):339-350. PubMed ID: 32369402 [TBL] [Abstract][Full Text] [Related]
2. Renin-Angiotensin System Blockers and the COVID-19 Pandemic: At Present There Is No Evidence to Abandon Renin-Angiotensin System Blockers. Danser AHJ; Epstein M; Batlle D Hypertension; 2020 Jun; 75(6):1382-1385. PubMed ID: 32208987 [TBL] [Abstract][Full Text] [Related]
3. Covid-19: the renin-angiotensin system imbalance hypothesis. Lanza K; Perez LG; Costa LB; Cordeiro TM; Palmeira VA; Ribeiro VT; Simões E Silva AC Clin Sci (Lond); 2020 Jun; 134(11):1259-1264. PubMed ID: 32507883 [TBL] [Abstract][Full Text] [Related]
4. The mechanistic overview of SARS-CoV-2 using angiotensin-converting enzyme 2 to enter the cell for replication: possible treatment options related to the renin-angiotensin system. Offringa A; Montijn R; Singh S; Paul M; Pinto YM; Pinto-Sietsma SJ Eur Heart J Cardiovasc Pharmacother; 2020 Sep; 6(5):317-325. PubMed ID: 32464637 [TBL] [Abstract][Full Text] [Related]
5. COVID-19 and renin-angiotensin system inhibition: role of angiotensin converting enzyme 2 (ACE2) - Is there any scientific evidence for controversy? Aleksova A; Ferro F; Gagno G; Cappelletto C; Santon D; Rossi M; Ippolito G; Zumla A; Beltrami AP; Sinagra G J Intern Med; 2020 Oct; 288(4):410-421. PubMed ID: 32459372 [TBL] [Abstract][Full Text] [Related]
7. A brief review of interplay between vitamin D and angiotensin-converting enzyme 2: Implications for a potential treatment for COVID-19. Malek Mahdavi A Rev Med Virol; 2020 Sep; 30(5):e2119. PubMed ID: 32584474 [TBL] [Abstract][Full Text] [Related]
8. The interaction of RAAS inhibitors with COVID-19: Current progress, perspective and future. Zhang J; Wang M; Ding W; Wan J Life Sci; 2020 Sep; 257():118142. PubMed ID: 32712300 [TBL] [Abstract][Full Text] [Related]
9. Endocrine aspects of ACE2 regulation: RAAS, steroid hormones and SARS-CoV-2. Young MJ; Clyne CD; Chapman KE J Endocrinol; 2020 Nov; 247(2):R45-R62. PubMed ID: 32966970 [TBL] [Abstract][Full Text] [Related]
10. SARS-CoV-2 pandemic and research gaps: Understanding SARS-CoV-2 interaction with the ACE2 receptor and implications for therapy. Datta PK; Liu F; Fischer T; Rappaport J; Qin X Theranostics; 2020; 10(16):7448-7464. PubMed ID: 32642005 [TBL] [Abstract][Full Text] [Related]
11. The Yin and Yang of ACE/ACE2 Pathways: The Rationale for the Use of Renin-Angiotensin System Inhibitors in COVID-19 Patients. Zamai L Cells; 2020 Jul; 9(7):. PubMed ID: 32708755 [TBL] [Abstract][Full Text] [Related]
12. Discovery and characterization of ACE2 - a 20-year journey of surprises from vasopeptidase to COVID-19. Hooper NM; Lambert DW; Turner AJ Clin Sci (Lond); 2020 Sep; 134(18):2489-2501. PubMed ID: 32990314 [TBL] [Abstract][Full Text] [Related]
13. Interaction of SARS-CoV-2 and Other Coronavirus With ACE (Angiotensin-Converting Enzyme)-2 as Their Main Receptor: Therapeutic Implications. Davidson AM; Wysocki J; Batlle D Hypertension; 2020 Nov; 76(5):1339-1349. PubMed ID: 32851855 [TBL] [Abstract][Full Text] [Related]
14. Disequilibrium between the classic renin-angiotensin system and its opposing arm in SARS-CoV-2-related lung injury. Sarzani R; Giulietti F; Di Pentima C; Giordano P; Spannella F Am J Physiol Lung Cell Mol Physiol; 2020 Aug; 319(2):L325-L336. PubMed ID: 32639866 [TBL] [Abstract][Full Text] [Related]
15. Angiotensin-Converting Enzyme 2: SARS-CoV-2 Receptor and Regulator of the Renin-Angiotensin System: Celebrating the 20th Anniversary of the Discovery of ACE2. Gheblawi M; Wang K; Viveiros A; Nguyen Q; Zhong JC; Turner AJ; Raizada MK; Grant MB; Oudit GY Circ Res; 2020 May; 126(10):1456-1474. PubMed ID: 32264791 [TBL] [Abstract][Full Text] [Related]
16. SARS-CoV-2 and ACE2: The biology and clinical data settling the ARB and ACEI controversy. Chung MK; Karnik S; Saef J; Bergmann C; Barnard J; Lederman MM; Tilton J; Cheng F; Harding CV; Young JB; Mehta N; Cameron SJ; McCrae KR; Schmaier AH; Smith JD; Kalra A; Gebreselassie SK; Thomas G; Hawkins ES; Svensson LG EBioMedicine; 2020 Aug; 58():102907. PubMed ID: 32771682 [TBL] [Abstract][Full Text] [Related]
17. A mechanistic model and therapeutic interventions for COVID-19 involving a RAS-mediated bradykinin storm. Garvin MR; Alvarez C; Miller JI; Prates ET; Walker AM; Amos BK; Mast AE; Justice A; Aronow B; Jacobson D Elife; 2020 Jul; 9():. PubMed ID: 32633718 [TBL] [Abstract][Full Text] [Related]
18. Drugs acting on renin angiotensin system and use in ill patients with COVID-19. Alexandre J; Cracowski JL; Richard V; Bouhanick B; Therapie; 2020; 75(4):319-325. PubMed ID: 32553503 [TBL] [Abstract][Full Text] [Related]
19. Organ-protective effect of angiotensin-converting enzyme 2 and its effect on the prognosis of COVID-19. Cheng H; Wang Y; Wang GQ J Med Virol; 2020 Jul; 92(7):726-730. PubMed ID: 32221983 [TBL] [Abstract][Full Text] [Related]
20. Renin-Angiotensin-Aldosterone System Inhibitors in Patients with Covid-19. Vaduganathan M; Vardeny O; Michel T; McMurray JJV; Pfeffer MA; Solomon SD N Engl J Med; 2020 Apr; 382(17):1653-1659. PubMed ID: 32227760 [No Abstract] [Full Text] [Related] [Next] [New Search]